Scientists at Beigene Ltd. and Beigene Switzerland GmbH have divulged serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of inflammatory and autoimmune diseases.
Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of inflammatory bowel disease (IBD).
Atai Life Sciences has identified monoamine transporter modulators reported to be useful for the treatment of post-traumatic stress, eating disorders and obsessive-compulsive disorder.
Nimbus Therapeutics LLC has disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of alopecia, muscle atrophy and more.
Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists of GIPR/GLP-1/GCGR reported to be useful for the treatment of type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, neurodegeneration, fibrosis and cardiovascular disorders.
Scientists at Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have described GTPase KRAS and/or its mutant inhibitors reported to be useful for the treatment of cancer.
RSS